Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae

By sjmartinez • August 5, 2023

Maas L, Gao R, Cusumano V, Spartz E, Chowdhury R, Krishna M, Lazarev M, Melia J, Selaru F, Sharma S, Limketkai B, Parian A. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae. Dig Dis Sci. 2023 Aug 4. doi: 10.1007/s10620-023-08060-7. Epub ahead of print. PMID: 37540392.

Tags: Crohn’s disease, Digestive Diseases, General Internal Medicine, inflammatory bowel disease, Perianal disease, Perianal fistula, Publications, Resident, Tumor necrosis factor inhibitor

A prospective international multisite randomized controlled trial of water exchange with and without distal cap(s) in adenoma detection

Leung FW, Cadoni S, Chen L, Chen Y, Cheng CL, Cheung R, Dixit V, Elashoff D, Friedland S, Gallittu P, Hsieh YH, Cheng CH, Jacob[...]

Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis

Lacy BE, Shin AS, Cangemi DJ, Yang Y, Zhao S, Rosenbaum DP. Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post[...]

Intestinal macrophages modulate synucleinopathy along the gut-brain axis

De Schepper S, Konstantellos V, Conway JA, Sokolova D, Zaccagnini L, Cowley MV, Sierksma A, Yudina M, Edmonds M, Gavriouchkina D, Geary B, Wallis A,[...]